Team

Jay has more than 20 years of experience in the U.S. and Chinese biotech industry spanning R&D, intellectual property, business development, and legal aspects of the industry. He is a registered U.S. patent attorney with substantial experience and expertise in diagnostic and pharmaceutical patents. Jay is an editorial board member of the Biotechnology Law Report, a leading U.S.-based biotech law journal.

Previously, Jay spent ten years at Myriad Genetics Inc., most recently as Senior Vice President responsible for company-wide intellectual property, and was involved in R&D, marketing and business development. Prior to Myriad, Jay was a patent attorney at Alston & Bird LLP, and worked in R&D at Merck & Co., Inc.  He was a co-founder of Niiki Pharma Inc., a US-based startup oncology drug development company. Jay graduated with J.D. from the University of North Carolina School of Law, M.S. in biochemistry and molecular biology from Northwestern University in Evanston, Illinois, and B.S. in genetics from Fudan University in China.

Rich has 25 years IVD experience in the UK and EMEA regions. Having worked in sales for companies such as Helene Biosciences and Trinity Biotech, moved into B2B sales with Serologicals and BBI, followed by European commercial roles at Alere, Microvisk and Critical Diagnostics.

For the last 10 years Rich has been working as a commercial consultant helping companies from outside Europe access the lucrative CE market. Across a range of
clinical disciplines, he has successfully launched more than 10 novel point of care products across Europe and beyond. Rich brings a wealth of experience in both women’s health and point of care diagnostics and successful
establishment of indirect sales channels to maximise rapid market penetration. His successful network of niche IVD distributors have generated millions of dollars in sales over the years.
Rich graduated from Brunel University, West London with a BSc Hons in Medicinal, Agricultural and Environmental Chemistry.

Vini has more than 25 years of international experience in clinical and commercial roles. Thanks to his thorough knowledge of biomarkers and their clinical usefulness, he joined Cerca Biotech in April 2021 and holds the position of Scientific Advisor.

Before Cerca Biotech, Vinicio held multiple positions in Clinical and Marketing at large pharmaceutical (Sigma Tau, Glaxo) and medical device companies. These include role as Marketing
Manager and Clinical Consultant at Biosite (then acquired by Inverness Medical, Alere and Abbot) providing leadership to the clinical support for the portfolio of products in Acute Coronary Syndrome (ACS) and in the Heart
Failure and as a clinical team member for the BNP launch in EMEA and for the Stroke biomarkers Point of Care Test.
Always interested in new and promising biomarkers, he was also involved with Critical Diagnostic in the European market launch for the ST2 cardiac biomarker.
With Myriad Genetics Inc he worked on prognostic and predictive biomarkers in breast cancer, he led the International Team for the Endopredict (Sividon Diagnostic GmbH) launch in EMEA, gaining significant experience in
breast cancer.
Vinicio graduated with a M.Sc. (Biology, Biochemistry and Cellular Bioenergetic) from the University of Padua.